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ABSTRACT
Themechanisms of viral control and loss of viral control in chronically infected individuals with or without protective HLA class
I alleles are not fully understood.We therefore characterized longitudinally the immunological and virological features that may
explain divergence in disease outcome in 70 HIV-1 C-clade-infected antiretroviral therapy (ART)-naive South African adults, 35
of whom possessed protective HLA class I alleles. We demonstrate that, over 5 years of longitudinal study, 35% of individuals
with protective HLA class I alleles lost viral control compared to none of the individuals without protective HLA class I alleles
(P 0.06). Sustained HIV-1 control in patients with protective HLA class I alleles was characteristically related to the breadth of
HIV-1 CD8 T cell responses against Gag and enhanced ability of CD8 T cells to suppress viral replication ex vivo. In some
cases, loss of virological control was associated with reduction in the total breadth of CD8 T cell responses in the absence of
differences in HIV-1-specific CD8 T cell polyfunctionality or proliferation. In contrast, viremic controllers without protective
HLA class I alleles possessed reduced breadth of HIV-1-specific CD8 T cell responses characterized by reduced ability to sup-
press viral replication ex vivo. These data suggest that the control of HIV-1 in individuals with protective HLA class I alleles may
be driven by broad CD8 T cell responses with potent viral inhibitory capacity while control among individuals without protec-
tive HLA class I alleles may be more durable andmediated by CD8 T cell-independent mechanisms.
IMPORTANCE
Host mechanisms of natural HIV-1 control are not fully understood. In a longitudinal study of antiretroviral therapy (ART)-
naive individuals, we show that those with protective HLA class I alleles subsequently experienced virologic failure compared to
those without protective alleles. Among individuals with protective HLA class I alleles, viremic control was associated with
broad CD8 T cells that targeted the Gag protein, and CD8 T cells from these individuals exhibited superior virus inhibition
capacity. In individuals without protective HLA class I alleles, HIV-1-specific CD8 T cell responses were narrow and poorly
inhibited virus replication. These results suggest that broad, highly functional cytotoxic T cells (cytotoxic T lymphocytes [CTLs])
against the HIV-1 Gag protein are associated with control among those with protective HLA class I alleles and that loss of these
responses eventually leads to viremia. A subset of individuals appears to have alternative, non-CTLmechanisms of viral control.
These controllers may hold the key to an effective HIV vaccine.
HIV remains a global problem, and sub-Saharan Africa contin-ues to bear the brunt of the epidemic, accounting for 67% of
the infected people worldwide (1). Understanding the mecha-
nisms of natural viral control in HIV infection is crucial for the
identification of correlates of immune protection and for the de-
sign of an effective HIV vaccine. Previous studies have linkedHIV
control to a number of immunological factors, particularly HIV-
specific CD8 cytotoxic T lymphocytes (CTLs), which have been
demonstrated to play an important role (2–5). However, virus-
specific CD8T cell immune responses are not equally effective in
HIV control, as the majority of infected individuals progress to
disease despite the presence of these cells. HIV is able to evade
immune responses by developing mutations that mediate escape
from CTL recognition (6–12). In addition, the expression of cer-
tainHLA class Imolecules byHIV-infected patients, such asHLA-
B*27, HLA-B*57, HLA-B*58:01, HLA-B*81:01, and HLA-A*74:
01, is associated with better clinical disease outcomes in some
population settings (3, 13–18). HLA class I proteins present viral
peptides on the surface of antigen-presenting cells to CTLs, and a
major mechanism by which these protective alleles slow HIV dis-
ease progression is believed to be through CTL activity (18).
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The exact mechanisms of viral control among individuals with
protective HLA class I alleles are not fully understood. Analyses of
HIV long-term nonprogressors (LTNPs) and elite controllers
(ECs) suggest diverse and multifactorial mechanisms of natural
control of viremia. Factors contributing to elite control (undetect-
ableHIV viral load)may include attenuated viruseswith slow viral
evolution (19, 20), although replication-defective viruses are by
no means always present (21–24). HLA-B*57-positive elite con-
trollers maintained viral suppression despite the presence of es-
cape mutations, with evidence of CTL responses against unmu-
tated epitopes and de novo responses against epitopes with escape
mutations (25–27).
Although themajority ofHIV-1-infected individuals with con-
trolled viremia possess protective HLA class I alleles, a substantial
minority do not. For example, approximately 60% of Caucasian
elite controllers express HLA-B*27 and/or HLA-B*57, and ap-
proximately 60% of South African elite controllers express HLA-
B*57/58:01 and/or HLA-B*81:01 (28–30). In these cases of vire-
mic control in the absence of protective HLA molecules, it is
unclear whether immunological or other mechanisms of viral
control are involved. Moreover, among controllers with or with-
out protective HLA class I alleles, the infection is dynamic such
that loss of viral control is observed at least in a subset of individ-
uals whowere previously elite controllers. The best-studied exam-
ples of progression in elite controllers are of HLA-B*27-positive
subjects in whom escape within the immunodominant Gag
epitope appears to precipitate loss of viremic control (10, 31).
However, the mechanisms underlying the loss of viral control in
previous controllers are largely undetermined, and few studies
have addressed this issue. Thus, there is a clear need to identify
mechanisms responsible for control in individuals with long-term
chronic viral control, especially contrasting those with protective
HLA class I alleles versus those with nonprotective HLA class I
alleles in order to gain comprehensive understanding of viral con-
trol mechanisms that may be harnessed in prevention or thera-
peutic strategies.
Here, we investigated immunological and virological factors
mediating control and loss of virological control in a cohort of 70
HIV-1-infected antiretroviral therapy (ART)-naive South African
adults fromDurban, 35 of whom possessed protective HLA class I
alleles. Participants were followed longitudinally, with some
maintaining virological control throughout the study duration
whereas others experienced virologic failure. Specifically, we set
out to test the hypothesis that progression in viremic controllers
(VCs) is generally precipitated by CTL escape, in the setting of
diminished CD8 T cell breadth and polyfunctionality and low-
ered antiviral efficacy. To this end, we determined in these study
subjects the magnitude and breadth of CTL responses, the pres-
ence or emergence of CTL escape variants, CD8 T cell polyfunc-
tionality and proliferation, and the ex vivo ability of CTLs to sup-
press HIV-1 replication before and after virologic failure.
MATERIALS AND METHODS
Study subjects. Seventy HIV-1 subtype C-chronically infected partici-
pants from the Sinikithemba (SK) cohort in Durban, South Africa (3, 4,
32), were included in the current study. Participants were ART naive at all
the time points analyzed. The date of HIV infection is unknown for all
participants. Viral loads (VLs) for all subjects were measured every 6
months with the Roche Amplicor version 1.5 test, and CD4 T cell counts
were measured every 3 months by TruCount technology using flow cy-
tometry. The University of KwaZulu-Natal’s Biomedical Research Ethics
Committee approved the study, and all subjects provided written in-
formed consent for participation in the study.
Definitions of study groups and subgroups. The 70 study partici-
pants studied were divided into two groups based on their VLs at enroll-
ment: baseline viremic controllers (bVCs) were enrolled with a VL below
2,000 HIV RNA copies/ml and baseline noncontrollers (bNCs) were en-
rolled with a VL above 100,000 HIV RNA copies/ml. Longitudinal fol-
low-up of bVCs allowed us to further subdivide this group into 2 sub-
groups based on progression status: viremic controllers (VCs) were
defined as individuals who were enrolled with a VL of less than 2,000 HIV
RNA copies/ml andmaintained this low viral load for the entire period of
study (median of 4 years; interquartile range [IQR], 4 to 6 years), and
failing viremic controllers (fVCs)were defined as bVCswhowere enrolled
with a VL of2,000HIVRNA copies/ml but subsequently lost virological
control. We defined the loss of viral control as an increase in VL to more
than 10,000 HIV RNA copies/ml at a minimum of 2 time points during
the time of follow-up (median of 6 years; IQR, 5 to 6 years). These groups
are illustrated in Fig. 1.
HLA class I typing and ELISpot assay for the measurement of HIV-
specific immune responses. HLA class I typing was performed on
genomic DNA samples extracted from blood at the time of enrollment as
described previously (3). Of the 70 patients included in this study, 35
possessed protective HLA class I alleles (A*74:01, B*57, B*58:01, and
B*81:01) (3, 13–17). These HLA alleles were selected as the principal pro-
tective alleles and are consistently the most protective that have been
identified in the Durban study population (17, 30, 33). The HLAs that
restricted responses seen in the nonprotective HLA group include HLAs
B*15:10, B*08:01, B*44:03, B*14:02, B*42:01, B*45:01, B*39:10, and
B*40:01 alleles. HIV immune responses were enumerated from frozen
and freshly isolated whole peripheral blood mononuclear cells (PBMCs)
by the gamma interferon (IFN-) enzyme-linked immunosorbent spot
(ELISpot) assay as previously described (3, 34). PBMCs were stimulated
with 410 consensus clade C 18-mer overlapping peptides (OLPs) covering
the entire proteome followed by confirmations with individual peptides
within a reactive pool at a final concentration of 2 g/ml and consensus
clade C optimal peptides corresponding to each patient’s HLA-B allele,
also at a final concentration of 2 g/ml per peptide.
Sequencing of the gag gene. Population sequencing of the gag gene
was performed as previously described (32). In brief, viral RNA was iso-
lated from plasma samples followed by reverse transcription to generate
cDNA. The gag sequences were amplified by nested PCR, purified, and
directly sequenced. The sequences were then analyzed using the ABI
3130xl genetic analyzer (Applied Biosystems, Foster City, CA, USA). Se-
quence data were aligned to HIV-1 subtype B reference strain HXB2
(GenBank accession number K03455), and insertions with respect to
HXB2 were stripped before further analysis. Editing and alignment of
sequences were carried out using the Sequencher version 5 (Gene Codes
Corp., Ann Arbor, MI, USA) and SeAl version 2.0a11 software, available
online (http://tree.bio.ed.ac.uk/software/seal/) (A. Rambaut,Department
of Zoology, University of Oxford, Oxford, United Kingdom), respec-
tively. Some of the baseline Gag sequences used in this study were ob-
tained from the GenBank database (accession numbers HM593195,
HM593368.1, HM593206.1, HM593194.1, FJ198948.1, HM593285,
HM593444, HM593233.1, HM593353.1, HM593360.1, HM593247,
HM593347.1, HM593320, HM593295, and HM593217). New Gag se-
quences generated in this study are available in GenBank.
Flow cytometry and intracellular cytokine staining assay. Freshly
thawed cryopreserved PBMCs were left to rest at 37°C with 5% CO2 for 4
h. A total of 200,000 PBMCs per well were stimulated with consensus
clade C Gag peptide pools (2 g/ml/peptide), and phytohemagglutinin
(PHA)-stimulated PBMCs (2 g/ml) were used as a positive control. An-
ti-CD107a-phycoerythrin (PE)-Cy7 (BD Biosciences, San Jose, CA, USA)
antibody and Golgi stop and Golgi plug (Sigma-Aldrich, St. Louis, MO,
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USA) were added in each well, and cells were incubated overnight at 37°C
with 5% CO2.
Intracellular cytokine staining was performed as described previously
(35, 36). The cells were then acquired on a flow cytometer (LSR II; BD
Biosciences). The 5 functions studied were CD107a, IFN-, interleukin-2
(IL-2), macrophage inflammatory protein 1 (MIP-1), and tumor ne-
crosis factor alpha (TNF-). Between 30,000 and 100,000 events were
acquired per sample. The acquired data were analyzed by FlowJo version
9.6.2 (Tree Star, SanCarlos, CA,USA). The gating strategy is shown in Fig.
2A. Boolean gating was performed in order to allow creation of a full array
of possible combinations of up to 32 response patterns. Positive responses
were reported after background correction, and the percentage of
epitope-specific CD8 T cell responses had to be at least two times higher
than background for each tested marker. PESTLE (version 1.6.2) and
SPICE 5.0 (Mario Roederer, ImmunoTechnology Section, Vaccine Re-
search Center, NIH, Bethesda, MD, USA) were used to analyze the mul-
tifunctional data.
CFSE proliferation assay. Freshly thawed cryopreserved PBMCswere
left to rest at 37°C with 5% CO2 for 4 h and then stained with carboxy-
fluorescein succinimidyl ester (CFSE) dye (Invitrogen, Paisley, United
Kingdom) for 7 min at 37°C with 5% CO2. A total of 400,000 CFSE-
labeled PBMCs per well were stimulated with Gag peptide pools (2 g/
ml/peptide) or PHA (2 g/ml) as a positive control, followed by incuba-
tion at 37°C with 5% CO2 for 7 days. After 7 days, cells were then washed
and stained with a live/dead marker (fixable blue dead-cell stain) (Invit-
rogen) for 10 min, followed by surface staining with anti-CD3 allophyco-
cyanin (APC) H7, anti-CD4 Alexa 700, and anti-CD8 VD 500 (BD Bio-
sciences) and a dump channel panel comprising anti-CD14 Pacific Blue,
anti-CD19 Pacific Blue, and anti-CD16/56 Pacific Blue antibodies (Bio-
Legend, SanDiegoCA,USA). The cells were incubated in the dark at room
temperature for 20 min and then washed twice. Between 30,000 and
100,000 events were acquired per well (sample). The acquired data were
analyzed by FlowJo version 9.6.2 (Tree Star). The gating strategy is shown
in Fig. 2B. GraphPad Prism version 5.0a software (GraphPad Software,
San Diego, CA, USA) was used to analyze group data sets.
Ex vivo viral inhibition assay. An ex vivo viral inhibition assay was
carried out to determine the ability of CD8 T cells to suppress virus
replication by measuring the amount of HIV p24 antigen as previously
described (36, 37). Log inhibition values were calculated by subtracting
log10 p24 values of the infectedCD4
T cells coculturedwithCD8T cells
from log10 p24 values of the infectedCD4
T cells without CD8T cells at
day 7. GraphPad Prism version 5.0a software (GraphPad Software, San
Diego, CA, USA) was used to analyze group data sets.
Statistical analysis.GraphPad Prism version 5.0a was used to analyze
the results. Statistical analysis was performed on Prism using the Mann-
Whitney test,Wilcoxonmatched pairs test, Fisher exact test, and Kruskal-
Wallis test. Comparison between groups was corrected for multiple com-
parisons. To adjust for time between time points or measurements before
and after loss of viral control, we used linear mixed models. A P value
below 0.05 was considered significant.
Nucleotide sequence accession numbers. New Gag sequences gen-
erated in this study are available in GenBank under accession numbers
KX347069 to KX347092.
RESULTS
Loss of virological control is exclusively encountered among
viremic controllers with protective HLA class I alleles. The viral
load andCD4 counts of the 70 study subjects are shown in Table 1.
During the median 5-year follow-up, 7/20 of the subjects express-
ing protective HLA class I alleles who were viremic controllers at
baseline had progressed to viral loads of 10,000 copies/ml. In
contrast, 0/10 of the subjects not expressing protectiveHLA class I
alleles who were viremic controllers at baseline had progressed to
viral loads of 10,000 copies/ml (P 	 0.06, Fisher’s exact test)
(Fig. 1 and 3). It is important to note that individuals with protec-
FIG 1 Groups and subgroups of study participants. The 70 HIV-1 subtype C-chronically infected participants were from the Sinikithemba (SK) cohort in
Durban, South Africa. Viremic controllers (VC/
) were enrolled with a VL of below 2,000 HIV RNA copies/ml and maintained this low VL for the entire
enrollment duration. Failing VCs (fVCs) were enrolled with a VL of below 2,000 HIV RNA copies/ml, and the VL increased to more than 10,000 HIV RNA
copies/ml at a minimum of 2 subsequent time points.
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tive HLA class I alleles who ended up as failing viremic controllers
(fVC) had a trend toward higher baseline viral load than those
who maintained control (VC) (P 	 0.06, Mann-Whitney test),
suggesting that the process of control was already inmotion in the
former. There were some individuals whose viral load upon fol-
low-up was above 2,000 but below 10,000 copies/ml, and these
individuals (intermediates) were excluded from analysis of mech-
anisms of loss of control. We focused on the 2 subgroups with
extreme divergent outcomes in order to better understand the
factors responsible for the control among the viremic controllers
with or without protective HLA class I alleles (VC/
) and lack of
viral control among fVC/
 subgroups. Overall, these data sug-
gested that the mechanisms responsible for viral control among
those without protective HLA class I alleles are more durable than
the mechanisms in those with protective alleles.
Increased breadth of CD8 T cell responses against HIV-1
Gag in baseline viremic controllers with protective HLA class I
alleles.We next characterized HIV-specific CD8 T cell immune
responses in the study participants with the ELISpot assay using
consensus subtype C overlapping peptides spanning the entire
proteome followed by confirmations with individual peptides
within a reactive pool. The breadth of HIV-specific responses
overall did not differ significantly between the groups (Fig. 4A).
However, there was a significant difference in the breadth of Gag-
specific CD8 T cell responses between the 4 groups (P value 	
0.01; Kruskal-Wallis test), bVCswith protectiveHLA class I alleles
targeting a significantly higher number of Gag epitopes than base-
line noncontrollers (bNCs) with protective HLA class I alleles (P
value	 0.004; Mann-Whitney test) (Fig. 4B). In contrast, among
individuals without protective HLA class I alleles there were no
significant differences between bVCs and bNCs in Gag-specific
breadth (P value, 0.10;Mann-Whitney test). No significant differ-
ences between the groups were observed when comparing non-
Gag proteins individually (data not shown). These differences are
further illustrated by comparisons between Gag and Nef breadths
in the four study groups (Fig. 4C to F), with bVC groups possess-
ing significantly broader Gag than Nef responses. Taken together,
these observations are consistent with previous findings indicat-
ing that broad targeting of Gag but notNefmay contribute toHIV
control among viremic controllers (4, 38–40).
Lossof virologic control is associatedwith the loss ofCD8T
cell responses. In order to identify HIV-specific CD8 T cell im-
mune response changes associated with the loss of viral control,
samples were evaluated at baseline (before loss of control) time
point and at the time point when their VL first increased to above
10,000 copies/ml (after loss of virologic control).
A significant reduction in the overall breadth of CD8 T cell
FIG 2 Gating strategy for polyfunctionality (A) and proliferative capacity
(B) of CD8 T cells upon stimulation with Gag peptide pools. For poly-
functionality of CD8 T cells (A), the initial gating was on lymphocytes
followed by the forward scatter height (FCS-H) versus forward scatter area
(FSC-A) to eliminate the doublets. We then gated on the live CD3 T cell
population followed by gating of CD8 and CD4 T cell populations,
followed by the gating for individual respective functions (set based on the
negative control); these were used to identify positive responses. For the
proliferation of CD8 T cells (B), the initial gating was on lymphocytes
followed by gating on the live CD3 T cell population and then on CD8
and CD4 T cell populations. The next gates were set on the CFSE-negative
CD8 population to identify proliferated CD8 T cell populations. The
individual gating for proliferating cells was set based on the negative con-
trol (no stimulation); these were used to identify positive responses by
subtraction from stimulated proliferating population. SSC, side scatter;
FITC, fluorescein isothiocyanate.
TABLE 1 Characteristics of study subjects





Median VL, HIV RNA
copies/ml (IQR) P value
Median CD4 count,
cells/mm3 (IQR) P value
Viremic controllers 0.77 0.09
 20 5 (4–6) 487 (283–1,252) 509 (459–684)

 10 5 (4–6) 613 (399–1,213) 669 (550–865)
Noncontrollers 0.26 0.56
 15 4 (3–6) 156,000 (118,000–192,000) 329 (257–377)

 25 3 (2.5–4) 209,000 (132,000–330,000) 373 (260–478)
a Protective HLA alleles: HLAs B*57, B*58:01, B*81:01, and A*74:01.
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responses and in Gag-specific breadth was observed among the
fVC over time (P 	 0.02 and P 	 0.003; linear mixed models
[Fig. 4G and H]). The group of baseline noncontrollers with pro-
tective HLA class I alleles showed a trend in reduction of overall
CD8Tcell response breadth (P	 0.06) andGag-specific breadth
(P	 0.09; linear mixed models) (Fig. 4G and H). In contrast, no
changes in overall breadth or in Gag breadth were observed in
VC or VC
 groups (Fig. 4G and H) or in Nef-specific responses
among the fVC subgroup over time (P value, 0.14; linear mixed
models) (data not shown).
We next wanted to identify the specific epitopes in failing vire-
mic controllers with protective HLA alleles (fVC) that were lost
over time. The majority (73%) of the total CD8 T cell responses
detected at baseline were no longer detectable by ELISpot assay at
the time of virological failure, and their identities are shown in
Table 2. Interestingly, in 3 subjects, therewas an emergence of new
CD8 T cell specificities at virologic failure (Table 2). The specific
epitopes targeted byVC andVC
 subgroups are shown inTables
3 and 4, respectively. Althoughwe foundno significant loss or gain
of responses in these 2 subgroups, cumulatively VC lost 24 re-
sponses and gained 36 responses, while among theVC
 subgroup,
there were 13 responses lost and 4 gained at a later time point.
Overall, these data demonstrated the maintenance of overall
breadth over time in the VC and VC
 subgroups.
Escape mutations within Gag only partially explain the loss
of virological control in fVCs with protective HLA alleles. We
next investigated whether the observed loss of virologic control
associated with loss of immune responses was primarily linked to
emergence of viral escapemutations as previously suggested (6–9,
11, 12, 41, 42). Longitudinal population gag sequencing was per-
formed from plasma samples at baseline and after loss of control
for the fVC subjects and at baseline and available later time
points for the viremic controllers with and without protective
HLA class I alleles (VC andVC
).We assessedmutations within
epitopes restricted by the patients’ protective HLA class I alleles
plus epitopes restricted by the otherHLAB alleles that the subjects
possess. The HIV-1 clade C Gag consensus sequence was used as
reference for comparison in this analysis. The percentage of vari-
ant sequences was calculated by counting the number of epitopes
with sequence changes divided by the cumulative number of
epitopes restricted by each patient’s HLA types that were tested
multiplied by 100: % variant sequences	 [(number of variant
sequences/cumulative number of epitopes tested on all sub-
jects)  100].
For the fVC subjects, the proportion of epitopes restricted by
the HLA alleles expressed, and carrying variants, did not differ
before and after loss of viremic control (51% before versus 53%
after [Fig. 5A]). Thus, the reduction in epitopes targeted was un-
related to escape. Further work is needed to better understand the
mechanisms involved in loss ofCD8T cell responses over time in
the absence of viral escape, as demonstrated by the lack of viral
escape in well-characterizedGag epitopes restricted by the protec-
FIG 3 Longitudinal viral load (A and C) and absolute CD4 T cell count (B andD) patterns among baseline viremic controllers with and without protective HLA
alleles. fVC, failing viremic controllers with protective HLA alleles (enrolled with a viral load of2,000 HIV RNA copies/ml and later lost control, n	 7; loss
of control is defined by an increase in viral load to10,000 HIV RNA copies/ml at 2 or more time points during follow-up); VC/
, viremic controllers with or
without protective HLA alleles (maintained viral load of2,000 HIV RNA copies/ml for the entire course of follow-up).
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tive HLA-B*57/58:01/81:01, despite the loss of responses to these
epitopes (data not shown).
Furthermore, Gag epitope sequences of theVC andVC
 sub-
groups were assessed at baseline (samples were available only at
this time point). The VC subgroup displayed a high proportion
of immune escape variants in epitopes restricted by the host HLA
alleles (70% [Fig. 5B]). These data suggest that controllers with
protective HLA class I alleles maintained viral suppression despite
the presence of escapemutations, with evidence of CTL responses
against wild-type epitopes and some epitopes with escape muta-
tions. In contrast, the VC
 subgroup displayed fewer variant
epitopes (49% [Fig. 5C]) and most did not elicit detectable CD8
FIG 4 Baseline (A to F) and longitudinal (G and H) ELISpot screening of HIV-specific T cell responses. Overall breadth to the entire HIV proteome (A) and
breadth of Gag-specific immune responses (B) among individuals with or without protective HLA alleles (bVC/
 and bNC/
). An ELISpot matrix assay
followed by confirmationwith overlapping peptides spanning the entireHIV-1 cladeCproteomewas used on thawedPBMCs. The breadth ofGag versusNefwas
assessed among the study groups: bVC (baseline viremic controllers with protective HLA alleles, n	 18) (C), bNC (baseline noncontrollers with protective
HLA alleles, n	 12) (E), bVC
 (baseline VCwithout protectiveHLA alleles, n	 9) (D), and bNC
 (baseline noncontrollers without protectiveHLA alleles, n	
20) (F). (G andH) Longitudinal ELISpot screening of HIV-specific T cell responses. (G)Overall breadth across entire HIV proteome. (H) Breadth of Gag among
viremic controllers (VC, n	 7), failing viremic controllers (fVC, n	 7), and baseline noncontrollers (bNC, n	 6) with protective HLA alleles and viremic
controllers (VC
, n	 5) without protective HLA alleles. PBMCs were stimulated with optimal peptides restricted only to individuals with HLA-B alleles and
spanning the whole HIV proteome. TP, time point.
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T cell responses. Although the number of subjects studied here is
limited, these data reveal that VC maintained viral control de-
spite having the highest prevalence of variant sequences either
within the epitope or in the 5 flanking amino acid residues com-
pared to individuals lacking protective HLA class I alleles.
No significant differences in the polyfunctionality or pro-
liferative capacity of CD8 T cells to explain the differences
in disease status.We next studied the ability of CD8 T cells to
produce diverse cytokines and proliferate upon stimulation
with Gag pool peptides at baseline and later time points. There
TABLE 2 Optimal HIV peptides targeted by failing viremic controllers (fVC) before and after loss of viral controlc
Subject no. and identifier
(controller status) and
peptide(s)
Allele(s) before or after loss of viremic control
Before After
1, SK-187 (fVC)
Gag B*08-EI8; B*58:01-NL11; B*58:01-TW10; B*58:01-QW9;
B*08-EL8
B*08-DI8; B*58:01-TW10; B*58:01-QW9





Gag B*57-WF9; B*57-ISW9; B*57-KF11; B*57-TW10 B*57-ISW9; B*57-KF11
Pol B*15:10-TIL9; B*57-AF10; B*57-VI9 B*15:10-TIL9




Gag B*07-GL9; B*57-ISW9; B*57-TW10; B*57-QW9 B*57-ISW9; B*57-QW9
Pol B*57-IW9; B*57-AF10; B*57-KI13 B*57-IW9; B*57-AF10
Tat/Rev/Vif/Vpr/Vpu — —
Env — —






Nef B*44-KY11; B*44-QY9; B*58:01-YY8; B*58:01-YT9; B*58:01-KY11 —
5, SK-024 (fVC)
Gag B*39:10-GL9; B*39:10-TL9; B*39:10-NL11; B*81:01-TL9 B*39:10-TL9
Pol B*81:01-LI9; B*81:01-SL10 —
Tat/Rev/Vif/Vpr/Vpu — —
Env — —
Nef B*81:01-RM9; B*81:01-RGF9 —
6, SK-079 (fVC)
Gag B*57-ISW9; B*57-KF11 B*57-KF11






Pol B*58:01-IAW9; B*58:01-SW10 B*58:01-IAW9
Tat/Rev/Vif/Vpr/Vpu B*58:01-VF9 B*58:01-QY10a
Env B*44-MY9; B*58:01-KW11; B*58:01-QL11 —
Nef B*44-KY11; B*44-QY9; B*58:01-HW9; B*58:01-KAF9;




b —, no response detected.
c Longitudinal ELISpot screening of HIV-specific CD8 T cell immune responses among failing viremic controllers (fVC, n	 7) with protective HLA alleles. PBMCs were
stimulated with optimal peptides restricted only to individual HLA-B alleles and spanning the whole HIV proteome.
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were no significant differences in CD8 T cell polyfunctional-
ity to explain the divergence in disease progression among the
subgroups (VC, fVC, VC
, and baseline noncontrollers
with protective HLA class I alleles) at baseline and later time
points (Fig. 6A). However, there was a nonsignificant trend
toward the CD8 T cells of viremic controllers with protective
HLA class I alleles having a higher proliferative capacity than
those of fVC at baseline (P value	 0.09, Mann-Whitney test)
TABLE 3 Optimal HIV peptides targeted by viremic controllers with protective HLA class I alleles (VC) at baseline and later time pointsc
Subject no. and identifier
(controller status) and
peptide(s)
Allele(s) at time point:
Baseline Latest time point
1, SK-199 (VC)
Gag B*57-ISW9; B*57-KF11; B*57-QW9 B*13-YV12a; B*13-GI11a; B*13-VV9a; B*57-WF9a; B*57-
ISW9; B*57-KF11; B*57-QW9
Pol B*57-IAW9 B*13-RI10a; B*57-IAW9; B*57-SW10a; B*57-AF10a; B*57-
KI13a; B*57-EY9a; B*57-FW11a
Tat/Rev/Vif/Vpr/Vpu —b B*13-LL9a; B*57-IW9a
Env — B*57-KW11a
Nef — B*13-RV9a; B*13-RI9a
2, SK-089 (VC)
Gag — B*58:01-WF9a; B*58:01-DW10a; B*58:01-QW9a
Pol B*57-FF9; B*57-VI9 B*15:03-FY10a; B*15:03-IY9a; B*15:03-RY9a; B*58:01-IAW9a
Tat/Rev/Vif/Vpr/Vpu — B*15:03-FY10a; B*58:01-LW9a
Env — B*58:01-KW11a; B*58:01-TWS10a
Nef — —
3, SK-282 (VC)
Gag B*44-AW11; B*58:01-DW10; B*58:01-TW10 B*58:01-QW9a





Gag B*39-GL9; B*39-NL11; B*81-HA9 B*39-NL11; B*81-TL9a





Gag B*15:01-VF9; B*15:10-VL10 B*15:03-VF9; B*15:10-GL9a











Gag A*74:01-RLY10; B*81-TL9; B*81-HA9; B*35-HA9 B*35-PY9a; B*35-HA9; B*81-HA9; B*81-TL9




Env B*35-DL9; B*81-RI10; B*81-IA9 B*35-DL9
Nef B*35-YF9a
a New response.
b —, no response detected.
c Longitudinal ELISpot screening of HIV-specific CD8 T cell immune responses among viremic controllers (VC, n	 7) with protective HLA alleles. PBMCs were stimulated
with optimal peptides restricted only to individual HLA-B alleles and spanning the whole HIV proteome.
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(Fig. 6B) and no significant differences at later time points
(Fig. 6C).
Viremic controllers without protective HLA class I alleles
display limited ex vivo CD8 T cell inhibition capacity com-
pared to viremic controllers with protective HLA class I alleles.
We further investigated the ability of CD8 T cells to suppress
viral replication ex vivo as a possible mechanism of viral control.
We used a viral inhibition assay to directly compare the virus-
inhibitory activity of CD8T cells ex vivo among VC, fVC, and
VC
 subgroups at baseline and later time points. Figure 7A to C
shows representative data for 1 VC, 1 VC
, and 1 fVC partici-
pant, respectively. We observed that viremic controllers with pro-
tective HLA class I alleles (VC) displayed significantly higher ex
vivo CD8 T cell inhibition capacity (Fig. 7A) than did viremic
controllers without protective HLA class I alleles (VC
) and fail-
ing viremic controllers with protective HLA class I alleles (fVC)
(Fig. 7B and C). VC subjects maintained this high ex vivo CD8
T cell inhibitory capacity while the VC
 subjects maintained the
low inhibitory capacity at later time points. However, in the 1
fVC subject studied, despite the subject displaying a reduced ex
vivoCD8T cell inhibitory capacity at baseline, we noted a further
reduction in the ex vivo CD8 T cell inhibitory capacity after the
subject lost viral control (Fig. 7C). Interestingly, there was also a
significant difference in the log10 p24 inhibition between the
viremic controllers with protective HLA class I alleles and vire-
mic controllers without protective HLA class I alleles, with the
FIG 5 Immunogenicity and viral escape in fVC subjects before and after loss
of viral control (A) and in VC (B) and VC
 (C) subjects at baseline. We
evaluated if the epitopes within the Gag region had variant sequences either
within the epitope or within the 5 flanking amino acids. HIV-1 clade C Gag
consensus sequence was used as reference for comparison in this analysis. We
assessed mutations within epitopes restricted by the patients’ protective HLA
class I alleles plus epitopes restricted by the other HLA-B alleles that the sub-
jects possessed. The percentage of variant sequences was calculated by count-
ing the number of epitopes with sequence changes divided by the cumulative
number of epitopes restricted by each patient’s HLA types that were tested
multiplied by 100 [(number of variant sequences/cumulative number of
epitopes tested)  100].
TABLE 4 Optimal HIV peptides targeted by viremic controllers without
protective HLA class I alleles (VC




Allele(s) at time point:























Gag B*39-TL9 B*39-TL9; B*39-NL11a



















b —, no response detected.
c Longitudinal ELISpot screening of HIV-specific CD8 T cell immune responses
among viremic controllers (VC
, n	 5) without protective HLA alleles. PBMCs were
stimulated with optimal peptides restricted only to individual HLA-B alleles and
spanning the whole HIV proteome.
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FIG 6 Polyfunctionality (A) and proliferative capacity (B and C) of CD8 T cells upon stimulation with Gag peptide pools—among viremic controllers
(VC), failing viremic controllers (fVC), baseline noncontrollers (bNC) with protective HLA alleles, and viremic controllers without protective HLA
alleles (VC
), at baseline and at later time points. The 5 functions studied were CD107a, IFN-, IL-2, MIP-1, and TNF-. On the pie charts (A), red
represents 5 functions, orange represents 4 functions, yellow represents 3 functions, green represents 2 functions, and blue represents 1 function. The
gating strategy is shown in Fig. 2A. Boolean gating was performed in order to allow creation of a full array of possible combinations of up to 32 response
patterns. Positive responses were reported after background correction, and the percentage of epitope-specific CD8 T cell responses had to be at least two
times higher than background for each tested marker. PESTLE (version 1.6.2) and SPICE 5.0 (Mario Roederer, ImmunoTechnology Section, Vaccine
Research Center, NIH, Bethesda, MD) were used to analyze the multifunctional data. The same subjects were assessed for the proliferation of CD8 T cells
at baseline (B) and latest time point (C). The gating strategy is shown in Fig. 2B. GraphPad Prism version 5.0a software (GraphPad Software, San Diego,
CA, USA) was used to analyze group data sets.
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former having CD8 T cells with greater viral inhibition capac-
ity (P value 	 0.02; Mann-Whitney test) (Fig. 7D). Taken to-
gether, these data show that CD8 T cells from viremic con-
trollers with protective HLA class I alleles are associated with
greater viral inhibitory capacity than are those of viremic con-
trollers without protective HLA class I alleles, suggesting an
alternative mechanism of control in the latter group.
DISCUSSION
The natural control of HIV has previously been linked to several
factors, including immunological factors, host genetics, and viral
factors in the HIV controller groups (viremic controllers, LTNPs,
and ECs). In chronically infected individuals, the evolution of
immunological and viral factors and their association with diver-
gent disease progression patterns have rarely been characterized.
Additionally, the findings on mechanisms of viral control in HIV
controllers using cross-sectional study design have been inconclu-
sive and therefore need resolving. In the current study, we ex-
plored the mechanisms of viral control and lack of viral control
among individuals with and without protective HLA class I
alleles. Viremic controllers with similar baseline clinical char-
acteristics but progressing to divergent viral load outcomes
were analyzed. We assessed at baseline and longitudinally the
CD8 T cell responses using the ELISpot assay, analyzed the
polyfunctionality and proliferative capacity of CD8 T cells
using flow cytometry, and analyzed Gag sequence evolution
and the ability of CD8 T cells to inhibit viral replication in an
ex vivo viral inhibition assay.
The loss of virological control was evident among 35%of base-
line viremic controllers with protective HLA class I alleles but not
among baseline viremic controllers without protectiveHLA class I
alleles. This unexpected findingmay suggest that viremic control-
lers withoutHLA class I alleles are less likely to subsequently prog-
ress, suggesting a durable mechanism of viral control in these in-
dividuals. Whereas previous studies suggest that the expression of
protective HLA class I alleles is a correlate of immune protection
from disease progression (43, 44), our study suggests that individ-
uals without protective HLA class I alleles who show virologic
control may have more durable, yet undefined mechanisms of
viral control.
We demonstrated that virologic control in subjects with pro-
tective HLA class I alleles was associated with greater breadth of
CD8 T cell responses to Gag, consistent with previous data on
the importance of Gag-specific responses in chronic HIV infec-
tion (4, 38). In addition, we observed a bias toward targeting of
greater breadth of HIV Gag epitopes compared to Nef indepen-
FIG 7 Ex vivo viral inhibition of NL4-3-infected CD4 T cells by autologous CD8 T cells. Infected CD4 T cells were cultured ex vivo with CD8 T cells
at a ratio of 1:1. Blue lines represent infected CD4 T cells alone, black lines represent the negative control (uninfected CD4 T cells), and the red lines
represent ex vivo coculture of infected CD4 T cells with autologous CD8 T cells. (A) Representative data for 1 VC at baseline and later time point. (B)
One VC
 at baseline and later time point. (C) Representative data for 1 fVC at baseline and later time point. (D) Log10 p24 inhibition of individual
subjects was calculated by subtracting log10 p24 values with CD8
 T cells from log10 p24 values without CD8
 T cells at day 7; here, we compared 5 VC
with 3 fVC and 5 VC
 individuals.
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dently of protective HLA class I allele expression among control-
lers. In contrast, baseline noncontrollers with or without protec-
tiveHLA class I alleles showed no bias toward targetingGag orNef
responses. These data further support previous work showing that
Gag CD8 T cell responses are associated with the control of viral
replication (3, 4, 38) while Nef CD8 T cell responses are associ-
ated with high viral load (39, 40). We also provide new evidence
that in controllers without protective HLA class I alleles, Gag
CD8 T cell responses do not appear to play a significant role in
viral control. It is possible that these individuals may have robust
innate immunity or cytolytic CD4 T cell responses (45). These
alternative mechanisms will be the focus of future investigations
in our cohort.
Longitudinal analysis of CD8T cell responses among viremic
controllers with and without protective HLA class I alleles
(VC/
) over time suggests that the maintenance of CD8 T cell
responses over time is important for sustained viral control during
chronic HIV infection. Further analysis of the longitudinal CD8
T cell responses of the failing viremic controllers with protective
HLA class I alleles (fVC subgroup) revealed that CD8 T cell
responses across the whole HIV proteome and Gag-specific re-
sponses in particular were lost over time. These observations sug-
gest that the loss of CD8 T cell responses may be related to the
loss of viral control in these individuals. This phenomenon was
also observed as a nonsignificant trend among baseline noncon-
trollers with protective HLA class I alleles, suggesting that this
process evolves over time as the disease progresses. However, one
important caveat is that we may have missed some responses due
to the use of consensus peptide sequences to stimulate PBMCs in
the current study. Nevertheless, our study strongly implicates di-
minishing CTL responses as the basis for loss of viremic control,
and we further identified the specific Gag responses that were no
longer detectable over time in this study. Future study will need to
further characterize some of the important non-Gag responses
that were also no longer detectable and contributed to loss of
viremic control.
The loss of CD8 T cell responses observed among the fVC
subgroup may be attributed to viral escape as a result of CTL
pressure. Analysis of the fVC subjects suggested that some of the
CD8 T cell responses were lost as a result of sequence variation
(viral escape) within the cognate epitopes. This is consistent with
other studies (12, 41, 42). However, some epitopes remained wild
type after loss of control and yet did not elicit detectable CD8 T
cell responses. Deciphering the underlyingmechanisms for loss of
these responses (not explained by viral escape) will require further
investigation. Nevertheless, our data unequivocally show that
these CD8 T cell responses underwent functional or pheno-
typic changes, and the mechanisms involved will require fur-
ther investigation. Our data also reveal that the loss of viral
control did not always occur as a result of escape. This is be-
cause there were no significant differences in the levels of es-
cape at baseline versus those after the loss-of-control time
point, suggesting that the loss of control is primarily related to
the loss of CD8 T cell responses.
Furthermore, previous studies have described mutations such
as T242N, A163G, and T186S as reverting mutations in HIV in-
fection, possibly due to their fitness cost (46, 47). In our study, the
T242N mutation was the most common mutation and reversion
to wild type occurred in 2 fVC subjects with no detectable CD8
T cell response, indicating that reversion in these 2 subjects re-
sulted from the loss of CTL pressure. However, in some individ-
uals there was no reversion observed despite the loss of CD8 T
cell responses. Previous studies show that some mutations within
Gag have a fitness cost to the virus (32, 48); however, compensa-
tory mutations can develop and restore viral fitness, or reversion
can occur, especially when the CTL pressure is lost. In our study, it
is possible that the fVC individuals may have developed com-
pensatorymutations that restored viral fitness, hence, the increas-
ing viral load in these individuals.
We also showed that VC subjects had a high level of escape,
with 70% of the epitopes at baseline having variant sequences.
Viral control was sustained in these individuals despite ongo-
ing evolution in plasma viruses, and this is in agreement with
some previous studies that showed that some elite controllers
maintained viral control despite ongoing viral replication and
evolution in plasma viruses and that they were able to develop
de novo immune responses to variant peptides (27, 49); how-
ever, we did not test for de novo immune responses in our
study.
We also demonstrated here using the viral inhibition assay that
viremic controllers with protective HLA class I alleles displayed
significantly higher ex vivo CD8 T cell inhibitory capacity than
did those viremic controllers without protective HLA class I al-
leles, who displayed limited ex vivo CD8 T cell inhibitory capac-
ity. These data may lend further support to alternative mecha-
nisms ofHIV control in VCswithout protectiveHLA class I alleles
where CD8 T cell responses may not be associated with virus
suppression. Other intrinsic factors, such as host restriction fac-
tors or viral mutations that affect interactions with these factors,
may play a role in the control of viremia in these individuals as
previously shown (50, 51).
Conclusion. Overall, our data indicate that individuals with-
out protective HLA class I alleles were less likely to lose viral con-
trol. Furthermore, we showed that the breadth of Gag CD8T cell
responses is the most significant correlate of viral control in indi-
viduals with protective HLA class I alleles and that the loss of
virologic control in individuals with protective HLA class I alleles
was related to a reduction in the total breadth of CD8 T cell
responses. The presence of escape mutations within epitopes only
partially explains divergent disease progression in the subgroups
studied, where the loss of some of the CD8 T cell responses
resulted from escape while the reasons for the loss of some others
were not known. Additional investigation of the function and
quality of the CD8 T cells showed that these factors did not
account for the divergent disease progression status observed
in the subgroups studied. Furthermore, the control of viremia
in individuals with protective HLA class I alleles was associated
with the ability of the CD8 T cells to inhibit viral replication.
Our findings here are consistent with those of Emu et al. (44),
who also demonstrated that HLA class I-restricted CD8 T
cells were responsible for viral control in elite controllers with
protective HLA alleles but not in those without those alleles.
We extend those findings by demonstrating that loss of CD8 T
cell breadth and viral inhibitory capacity explains loss of con-
trol in those with protective HLA alleles and that loss of the
responses was not always explained by viral escape. However,
further investigation will be required to characterize factors
that may be associated with control in individuals without pro-
tective HLA class I alleles.
Immune and Viral Correlates of Natural HIV-1 Control
August 2016 Volume 90 Number 15 jvi.asm.org 6829Journal of Virology
 o
n







We thankDenis Chopera for technical advice.We thank and acknowledge
the study participants from the Sinikithemba cohort.
FUNDING INFORMATION
This research was funded by grants from the South African Research
Chairs Initiative of the Department of Science and Technology and Na-
tional Research Foundation (NRF) (64809), the Victor Daitz Foundation,
and the Howard Hughes Medical Institute (HHMI) (55007427). Addi-
tional support was provided by the Organization for Women in Science
for the Developing World (OWSD) and the Mark and Lisa Schwartz
Foundation.
REFERENCES
1. UNAIDS. 2013. Global report: UNAIDS report on the global AIDS epi-
demic 2013. UNAIDS, Geneva, Switzerland.
2. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA,
Racz P, Tenner-Racz K, Dalesandro M, Scallon BJ, Ghrayeb J, Forman
MA, Montefiori DC, Rieber EP, Letvin NL, Reimann KA. 1999. Control
of viremia in simian immunodeficiency virus infection by CD8 lympho-
cytes. Science 283:857–860. http://dx.doi.org/10.1126/science.283.5403
.857.
3. Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, Chetty
S, Rathnavalu P, Moore C, Pfafferott KJ, Hilton L, Zimbwa P, Moore S,
Allen T, Brander C, Addo MM, Altfeld M, James I, Mallal S, Bunce M,
Barber LD, Szinger J, Day C, Klenerman P, Mullins J, Korber B,
Coovadia HM, Walker BD, Goulder PJR. 2004. Dominant influence of
HLA-B in mediating the potential co-evolution of HIV and HLA. Nature
432:769–775. http://dx.doi.org/10.1038/nature03113.
4. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I,
Moodley E, Reddy S, de Pierres C, Mncube Z, Mkhwanazi N, Bishop K,
van der Stok M, Nair K, Khan N, Crawford H, Payne R, Leslie A, Prado
J, Prendergast A, Frater J, McCarthy N, Brander C, Learn GH, Nickle
D, Rousseau C, Coovadia H, Mullins JI, Heckerman D, Walker BD,
Goulder P. 2007. CD8 T-cell responses to different HIV proteins have
discordant associations with viral load. Nat Med 13:46–53. http://dx.doi
.org/10.1038/nm1520.
5. Migueles SA, Connors M. 2010. Long-term nonprogressive disease
among untreated HIV-infected individuals: clinical implications of un-
derstanding immune control of HIV. JAMA 304:194–201. http://dx.doi
.org/10.1001/jama.2010.925.
6. Phillips RE, Rowland-Jones S, Nixon DF, Gotch FM, Edwards JP,
Ogunlesi AO, Elvin JG, Rothbard JA, Bangham CR, Rizza CR. 1991.
Human immunodeficiency virus genetic variation that can escape cyto-
toxic T-cell recognition. Nature 354:453–459. http://dx.doi.org/10.1038
/354453a0.
7. Koenig S, Conley AJ, Brewah YA, Jones GM, Leath S, Boots LJ, Davey
V, Pantaleo G, Demarest JF, Carter C. 1995. Transfer of HIV-1-specific
cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant
HIV variants and subsequent disease progression. Nat Med 1:330–336.
http://dx.doi.org/10.1038/nm0495-330.
8. Price DA, Goulder PJ, Klenerman P, Sewell AK, Easterbrook PJ, Troop
M, Bangham CR, Phillips RE. 1997. Positive selection of HIV-1 cytotoxic
T lymphocyte escape variants during primary infection. Proc Natl Acad
Sci U S A 94:1890–1895. http://dx.doi.org/10.1073/pnas.94.5.1890.
9. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, Meyers H, Nelson
JA, Gairin JE, Hahn BH, Oldstone MB, Shaw GM. 1997. Antiviral
pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) dur-
ing primary infection demonstrated by rapid selection of CTL escape vi-
rus. Nat Med 3:205–211. http://dx.doi.org/10.1038/nm0297-205.
10. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, Nowak MA,
Giangrande P, Luzzi G, Morgan B, Edwards A, McMichael AJ, Row-
land-Jones S. 1997. Late escape from an immunodominant cytotoxic
T-lymphocyte response associated with progression to AIDS. Nat Med
3:212–217. http://dx.doi.org/10.1038/nm0297-212.
11. Draenert R, Le Gall S, Pfafferott KJ, Leslie AJ, Chetty P, Brander C,
Holmes EC, Chang S, Feeney ME, Addo MM, Ruiz L, Ramduth D,
Jeena P, Altfeld M, Thomas S, Tang Y, Verrill CL, Dixon C, Prado JG,
Kiepiela P, Martinez-Picado J, Walker BD, Goulder PJR. 2004. Immune
selection for altered antigen processing leads to cytotoxic T lymphocyte
escape in chronic HIV-1 infection. J Exp Med 199:905–915. http://dx.doi
.org/10.1084/jem.20031982.
12. Goulder PJR, Watkins DI. 2004. HIV and SIV CTL escape: implications
for vaccine design. Nat Rev Immunol 4:630–640. http://dx.doi.org/10
.1038/nri1417.
13. Carrington M, O’Brien SJ. 2003. The influence of HLA genotype on
AIDS. Annu Rev Med 54:535–551. http://dx.doi.org/10.1146/annurev
.med.54.101601.152346.
14. Fellay J, Ge D, Shianna KV, Colombo S, Ledergerber B, Cirulli ET,
Urban TJ, Zhang K, Gumbs CE, Smith JP, Castagna A, Cozzi-Lepri A,
De Luca A, Easterbrook P, Günthard HF, Mallal S, Mussini C, Dalmau
J, Martinez-Picado J, Miro JM, Obel N, Wolinsky SM, Martinson JJ,
Detels R, Margolick JB, Jacobson LP, Descombes P, Antonarakis SE,
Beckmann JS, O’Brien SJ, Letvin NL, McMichael AJ, Haynes BF,
Carrington M, Feng S, Telenti A, Goldstein DB. 2009. Common genetic
variation and the control of HIV-1 in humans. PLoS Genet 5(12):
e1000791. http://dx.doi.org/10.1371/journal.pgen.1000791.
15. International HIV Controllers Study. 2010. The major genetic determi-
nants of HIV-1 control affect HLA class I peptide presentation. Science
330:1551–1557. http://dx.doi.org/10.1126/science.1195271.
16. Gao X, Bashirova A, Iversen AKN, Phair J, Goedert JJ, Buchbinder S,
Hoots K, Vlahov D, Altfeld M, O’Brien SJ, Carrington M. 2005. AIDS
restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis.
Nat Med 11:1290–1292. http://dx.doi.org/10.1038/nm1333.
17. Matthews PC, Adland E, Listgarten J, Leslie A, Mkhwanazi N, Carlson
JM, Harndahl M, Stryhn A, Payne RP, Ogwu A, Huang K-HG, Frater
J, Paioni P, Kloverpris H, Jooste P, Goedhals D, van Vuuren C, Steyn
D, Riddell L, Chen F, Luzzi G, Balachandran T, Ndung’u T, Buus S,
Carrington M, Shapiro R, Heckerman D, Goulder PJR. 2011. HLA-
A*7401-mediated control of HIV viremia is independent of its linkage
disequilibrium with HLA-B*5703. J Immunol 186:5675–5686. http://dx
.doi.org/10.4049/jimmunol.1003711.
18. Goulder PJR, Walker BD. 2012. HIV and HLA class I: an evolving rela-
tionship. Immunity 37:426–440. http://dx.doi.org/10.1016/j.immuni
.2012.09.005.
19. Wang B, Mikhail M, Dyer WB, Zaunders JJ, Kelleher AD, Saksena NK.
2003. First demonstration of a lack of viral sequence evolution in a non-
progressor, defining replication-incompetent HIV-1 infection. Virology
312:135–150. http://dx.doi.org/10.1016/S0042-6822(03)00159-4.
20. Sandonís V, Casado C, Alvaro T, Pernas M, Olivares I, García S,
Rodríguez C, del Romero J, López-Galíndez C. 2009. A combination of
defective DNA and protective host factors are found in a set of HIV-1
ancestral LTNPs. Virology 391:73–82. http://dx.doi.org/10.1016/j.virol
.2009.05.022.
21. Lamine A, Caumont-Sarcos A, Chaix M-L, Saez-Cirion A, Rouzioux C,
Delfraissy J-F, Pancino G, Lambotte O. 2007. Replication-competent
HIV strains infect HIV controllers despite undetectable viremia (ANRS
EP36 study). AIDS 21:1043–1045. http://dx.doi.org/10.1097/QAD
.0b013e3280d5a7ac.
22. Wong JK. 1997. Recovery of replication-competent HIV despite pro-
longed suppression of plasma viremia. Science 278:1291–1295. http://dx
.doi.org/10.1126/science.278.5341.1291.
23. Blankson JN, Bailey JR, Thayil S, Yang H-C, Lassen K, Lai J, Gandhi SK,
Siliciano JD, Williams TM, Siliciano RF. 2007. Isolation and character-
ization of replication-competent human immunodeficiency virus type 1
from a subset of elite suppressors. J Virol 81:2508–2518. http://dx.doi.org
/10.1128/JVI.02165-06.
24. Miura T, Brockman MA, Brumme CJ, Brumme ZL, Carlson JM,
Pereyra F, Trocha A, Addo MM, Block BL, Rothchild AC, Baker BM,
Flynn T, Schneidewind A, Li B, Wang YE, Heckerman D, Allen TM,
Walker BD. 2008. Genetic characterization of human immunodeficiency
virus type 1 in elite controllers: lack of gross genetic defects or common
amino acid changes. J Virol 82:8422–8430. http://dx.doi.org/10.1128/JVI
.00535-08.
25. Bailey JR, Williams TM, Siliciano RF, Blankson JN. 2006. Maintenance
of viral suppression in HIV-1-infected HLA-B*57 elite suppressors de-
spite CTL escape mutations. J Exp Med 203:1357–1369. http://dx.doi.org
/10.1084/jem.20052319.
26. Bailey JR, Zhang H, Wegweiser BW, Yang H, Herrera L, Ahonkhai A,
Williams TM, Siliciano RF, Blankson JN. 2007. Evolution of HIV-1 in an
HLA-B*57-positive patient during virologic escape. J Infect Dis 196:50–
55. http://dx.doi.org/10.1086/518515.
27. O’Connell KA, Brennan TP, Bailey JR, Ray SC, Siliciano RF, Blankson
Koofhethile et al.
6830 jvi.asm.org August 2016 Volume 90 Number 15Journal of Virology
 o
n






JN. 2010. Control of HIV-1 in elite suppressors despite ongoing replica-
tion and evolution in plasma virus. J Virol 84:7018–7028. http://dx.doi
.org/10.1128/JVI.00548-10.
28. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, Baker
B, Trocha A, Rosenberg R, Mackey E, Ueda P, Lu Z, Cohen D, Wrin T,
Petropoulos CJ, Rosenberg ES, Walker BD. 2008. Genetic and immu-
nologic heterogeneity among persons who control HIV infection in the
absence of therapy. J Infect Dis 197:563–571. http://dx.doi.org/10.1086
/526786.
29. Leslie A, Price DA, Mkhize P, Bishop K, Rathod A, Day C, Crawford H,
Honeyborne I, Asher TE, Luzzi G, Edwards A, Rousseau CM, Mullins
JI, Tudor-Williams G, Novelli V, Brander C, Douek DC, Kiepiela P,
Walker BD, Goulder PJ. 2006. Targeting identical epitopes but restricted
by distinct HLA alleles from the same HLA supertype 1. J Immunol 177:
4699–4708. http://dx.doi.org/10.4049/jimmunol.177.7.4699.
30. Carlson JM, Listgarten J, Pfeifer N, Tan V, Kadie C, Walker BD,
Ndung’u T, Shapiro R, Frater J, Brumme ZL, Goulder PJR, Heckerman
D. 2012. Widespread impact of HLA restriction on immune control and
escape pathways of HIV-1. J Virol 86:5230–5243. http://dx.doi.org/10
.1128/JVI.06728-11.
31. Feeney ME, Tang Y, Roosevelt KA, Leslie AJ, McIntosh K, Karthas N,
Walker BD, Goulder PJR. 2004. Immune escape precedes breakthrough
human immunodeficiency virus type 1 viremia and broadening of the
cytotoxic T-lymphocyte response in an HLA-B27-positive long-term-
nonprogressing child. J Virol 78:8927–8930. http://dx.doi.org/10.1128
/JVI.78.16.8927-8930.2004.
32. Wright JK, Brumme ZL, Carlson JM, Heckerman D, Kadie CM,
Brumme CJ, Wang B, Losina E, Miura T, Chonco F, van der Stok M,
Mncube Z, Bishop K, Goulder PJR, Walker BD, Brockman MA,
Ndung’u T. 2010. Gag-protease-mediated replication capacity in
HIV-1 subtype C chronic infection: associations with HLA type and
clinical parameters. J Virol 84:10820–10831. http://dx.doi.org/10.1128
/JVI.01084-10.
33. Leslie A, Matthews P, Listgarten J, Carlson JM, Kadie C, Ndung’u T,
Brander C, Coovadia H, Walker BD, Heckerman D, Goulder PJR. 2010.
Additive contribution of HLA class I alleles in the immune control of
HIV-1 infection. J Virol 84:9879–9888. http://dx.doi.org/10.1128/JVI
.00320-10.
34. Thobakgale CF, Ramduth D, Reddy S, Mkhwanazi N, de Pierres C,
Moodley E, Mphatswe W, Blanckenberg N, Cengimbo A, Prendergast
A, Tudor-Williams G, Dong K, Jeena P, Kindra G, Bobat R, Coovadia
H, Kiepiela P, Walker BD, Goulder PJR. 2007. Human immunodefi-
ciency virus-specific CD8 T-cell activity is detectable from birth in the
majority of in utero-infected infants. J Virol 81:12775–12784. http://dx
.doi.org/10.1128/JVI.00624-07.
35. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J,
Lederman MM, Benito JM, Goepfert PA, Connors M, Roederer M,
Koup RA. 2006. HIV nonprogressors preferentially maintain highly func-
tionalHIV-specificCD8T cells. Blood 107:4781–4789. http://dx.doi.org
/10.1182/blood-2005-12-4818.
36. Ndhlovu ZM, Proudfoot J, Cesa K, Alvino M, Mcmullen A, Vine S,
Piechocka-Trocha A, Walker BD, Pereyra F. 2012. Elite controllers with
low to absent effector CD8 T cell responses maintain highly functional,
broadly directed central memory responses. J Virol 86:6959–6969. http:
//dx.doi.org/10.1128/JVI.00531-12.
37. Chen H, Piechocka-Trocha A, Miura T, Brockman MA, Julg BD, Baker
BM, Rothchild AC, Block BL, Schneidewind A, Koibuchi T, Pereyra F,
Allen TM, Walker BD. 2009. Differential neutralization of human im-
munodeficiency virus (HIV) replication in autologous CD4 T cells by
HIV-specific cytotoxic T lymphocytes. J Virol 83:3138–3149. http://dx
.doi.org/10.1128/JVI.02073-08.
38. Edwards BH, Bansal A, Sabbaj S, Bakari J, Mulligan MJ, Goepfert PA.
2002. Magnitude of functional CD8 T-cell responses to the Gag protein
of human immunodeficiency virus type 1 correlates inversely with viral
load in plasma. J Virol 76:2298–2305. http://dx.doi.org/10.1128/jvi.76.5
.2298-2305.2002.
39. Radebe M, Nair K, Chonco F, Bishop K, Wright JK, van der Stok M,
Bassett IV, Mncube Z, Altfeld M, Walker BD, Ndung’u T. 2011. Limited
immunogenicity of HIV CD8 T-cell epitopes in acute clade C virus in-
fection. J Infect Dis 204:768–776. http://dx.doi.org/10.1093/infdis/jir394.
40. Novitsky V, Gilbert P, Peter T, McLane MF, Gaolekwe S, Rybak N,
Thior I, Ndung’u T, Marlink R, Lee TH, Essex M. 2003. Association
between virus-specific T-cell responses and plasma viral load in human
immunodeficiency virus type 1 subtype C infection. J Virol 77:882–890.
http://dx.doi.org/10.1128/JVI.77.2.882-890.2003.
41. Prado JG, Honeyborne I, Brierley I, Puertas MC, Martinez-Picado J,
Goulder PJR. 2009. Functional consequences of human immunodefi-
ciency virus escape from an HLA-B*13-restricted CD8 T-cell epitope in
p1 Gag protein. J Virol 83:1018–1025. http://dx.doi.org/10.1128/JVI
.01882-08.
42. Prado JG, Prendergast A, Thobakgale C, Molina C, Tudor-Williams G,
Ndung’u T, Walker BD, Goulder P. 2010. Replicative capacity of human
immunodeficiency virus type 1 transmitted from mother to child is asso-
ciated with pediatric disease progression rate. J Virol 84:492–502. http:
//dx.doi.org/10.1128/JVI.01743-09.
43. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola
FM, Martino L, Hallahan CW, Selig SM, Schwartz D, Sullivan J,
Connors M. 2000. HLA B*5701 is highly associated with restriction of
virus replication in a subgroupofHIV-infected long termnonprogressors.
Proc Natl Acad Sci U S A 97:2709–2714. http://dx.doi.org/10.1073/pnas
.050567397.
44. Emu B, Sinclair E, Hatano H, Ferre A, Shacklett B, Martin JN, Mccune
JM, Deeks SG. 2008. HLA class I-restricted T-cell responses may contrib-
ute to the control of human immunodeficiency virus infection, but such
responses are not always necessary for long-term virus control. J Virol
82:5398–5407. http://dx.doi.org/10.1128/JVI.02176-07.
45. Soghoian DZ, Jessen H, Flanders M, Sierra-Davidson K, Cutler S, Pertel
T, Ranasinghe S, Lindqvist M, Davis I, Lane K, Rychert J, Rosenberg ES,
Piechocka-Trocha A, Brass AL, Brenchley JM, Walker BD, Streeck H.
2012. HIV-specific cytolytic CD4 T cell responses during acute HIV infec-
tion predict disease outcome. Sci Transl Med 4:123ra25.
46. Thobakgale CF, Prendergast A, Crawford H, Mkhwanazi N, Ramduth
D, Reddy S, Molina C, Mncube Z, Leslie A, Prado J, Chonco F,
Mphatshwe W, Tudor-Williams G, Jeena P, Blanckenberg N, Dong K,
Kiepiela P, Coovadia H, Ndung’u T, Walker BD, Goulder PJR. 2009.
Impact of HLA in mother and child on disease progression of pediatric
human immunodeficiency virus type 1 infection. J Virol 83:10234–10244.
http://dx.doi.org/10.1128/JVI.00921-09.
47. Matthews PC, Leslie AJ, Katzourakis A, Crawford H, Payne R, Pren-
dergast A, Power K, Kelleher AD, Klenerman P, Carlson J, Heckerman
D, Ndung’u T, Walker BD, Allen TM, Pybus OG, Goulder PJR. 2009.
HLA footprints on human immunodeficiency virus type 1 are associated
with interclade polymorphisms and intraclade phylogenetic clustering. J
Virol 83:4605–4615. http://dx.doi.org/10.1128/JVI.02017-08.
48. Miura T, Brumme ZL, Brockman MA, Rosato P, Sela J, Brumme CJ,
Pereyra F, Kaufmann DE, Trocha A, Block BL, Daar ES, Connick E,
Jessen H, Kelleher AD, Rosenberg E, Markowitz M, Schafer K, Vaida F,
Iwamoto A, Little S, Walker BD. 2010. Impaired replication capacity of
acute/early viruses in persons who become HIV controllers. J Virol 84:
7581–7591. http://dx.doi.org/10.1128/JVI.00286-10.
49. O’Connell KA, Hegarty RW, Siliciano RF, Blankson JN. 2011. Viral
suppression ofmultiple escapemutants by de novo CD8T cell responses
in a human immunodeficiency virus-1 infected elite suppressor. Retrovi-
rology 8:63. http://dx.doi.org/10.1186/1742-4690-8-63.
50. Battivelli E, Migraine J, Lecossier D, Yeni P, Clavel F, Hance AJ. 2011.
Gag cytotoxic T lymphocyte escape mutations can increase sensitivity of
HIV-1 to human TRIM5alpha, linking intrinsic and acquired immunity. J
Virol 85:11846–11854. http://dx.doi.org/10.1128/JVI.05201-11.
51. Granier C, Battivelli E, Lécuroux C, Venet A, Lambotte O, Schmitt-
Boulanger M, Delaugerre C, Molina J-M, Chakrabarti LA, Clavel F,
Hance AJ. 2013. Pressure from TRIM5 contributes to control of HIV-1
replication by individuals expressing protective HLA-B alleles. J Virol 87:
10368–10380. http://dx.doi.org/10.1128/JVI.01313-13.
Immune and Viral Correlates of Natural HIV-1 Control
August 2016 Volume 90 Number 15 jvi.asm.org 6831Journal of Virology
 o
n
 June 27, 2019 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
